Not independent
Tenure on this board
0.7 yrs
Meeting calendar
EVMN · Annual meeting · Tuesday, June 2, 2026
Evommune Inc
2 nominees · 2 ballot items.
Election of two Class I directors; Ratification of appointment of BDO USA, P.C. as independent registered public accounting firm for fiscal year ending December 31, 2026.
Market cap
$437M
1Y TSR
—
Board grade
C
Record date
Apr 6, 2026
Filing
DEF 14A
Meeting concluded · Jun 2, 2026
Follow how the vote landed and what changed on Evommune Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot2
- 1
Election of Directors
ManagementBoard: FORElect two Class I director nominees (Luis Peña and Eugene A. Bauer, M.D.) to hold office until the 2029 Annual Meeting.
- 2
Ratification of Appointment of Independent Registered Public Accounting Firm
ManagementBoard: FORRatify the Audit Committee’s appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
More detail
The Audit Committee has appointed BDO USA, P.C. as the Company’s independent registered public accounting firm for fiscal year 2026 and seeks shareholder ratification as a matter of good corporate practice. The proposal asks shareholders to ratify a longstanding relationship (BDO has audited the Company since 2022) to provide continuity in audit oversight. Management is submitting the selection for ratification to maintain governance best practices and to provide stockholders an opportunity to express their views; the Board and Audit Committee recommend voting for the ratification because the committee has reviewed BDO’s qualifications, independence, and performance and determined continuation aligns with the Company’s interests. If shareholders do not ratify, the Audit Committee will reconsider the appointment; even if ratified, the Audit Committee retains authority to change auditors if warranted.
Director elections
Nominees on the ballot2
Not independent
Tenure on this board
0.7 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | EQT Fund Management S.a r.l. | 13.7% | 4,929,633 | $113M |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 9.7% | 3,494,638 | $80M |
| 3 | Pivotal bioVenture Partners Investment Advisor LLC | 5.3% | 1,926,943 | $44M |
| 4 | Andera Partners | 5.3% | 1,897,362 | $44M |
| 5 | RTW INVESTMENTS, LP | 4.2% | 1,502,235 | $35M |
| 6 | MPM BioImpact LLC | 4.0% | 1,455,863 | $33M |
| 7 | Nan Fung Group Holdings Ltd | 4.0% | 1,441,032 | $33M |
| 8 | SymBiosis Capital Partners, LLC | 3.6% | 1,280,778 | $29M |
| 9 | EVENTIDE ASSET MANAGEMENT, LLC | 3.4% | 1,209,129 | $28M |
| 10 | PRICE T ROWE ASSOCIATES INC /MD/ | 3.1% | 1,104,409 | $25M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Evommune Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Indaptus Therapeutics IncINDP
Annual meeting·Aug 10, 2026·$287M
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$723M
Seer IncSEER
Annual meeting·Jul 28, 2026·$119M
Avanos Medical IncAVNS
Special meeting·Jul 22, 2026·$1.2B
Anaptysbio IncANAB
Annual meeting·Aug 11, 2026·$1.7B
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.7B
Reference
Frequently asked questions
- When is the Evommune Inc 2026 annual meeting?
- Evommune Inc (EVMN) holds its 2026 annual shareholder meeting on Tuesday, June 2, 2026.
- What is the record date for the Evommune Inc 2026 meeting?
- The record date for the Evommune Inc 2026 meeting is Monday, April 6, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Evommune Inc's 2026 meeting?
- The board is presenting 2 director nominees at the Evommune Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Evommune Inc 2026 meeting?
- Shareholders will vote on 2 proposals at the Evommune Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.